Researchers from the H. Lee Moffitt Cancer Center and Loyola University have published suggestions for the management of adverse effects associated with intravenous bisphosphonate therapy. The details of this report appeared in the June 2006 issue of the Annals of Oncology. Aredia and Zometa intravenous bisphosphonates are widely used to prevent or treat bone loss in patients with cancer and to treat cancer related hypercalcemia. The article cites that about 2 percent of patients have serious complications after receiving these intravenous drugs. The article goes on to state the list of complications and how if any may be prevented. (Cancer Consultants)